China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its adjustable intracranial thrombectomy stent, marking a significant milestone as the first domestically produced device of its kind in China for the treatment of acute ischemic stroke (AIS).
Currently, the primary clinical methods for treating AIS include intravenous thrombolysis and interventional therapy. Intravenous thrombolysis is typically preferred for patients with AIS onset within 4.5 hours, while interventional therapy offers a more extended treatment window. Mechanical thrombectomy is the preferred method within interventional therapy. Traditional thrombectomy stents used in clinical practice have a uniform diameter, which can pose challenges when trying to adapt to larger or narrower vascular occlusion sites, potentially complicating the surgical procedure. CGP’s adjustable stent addresses these challenges by improving the fit between the stent and the thrombus, thereby enhancing the effectiveness of the surgery and reducing damage to blood vessels, which in turn improves the safety of the procedure. Additionally, the stent features full-stent imaging, facilitating more precise operation by medical professionals.
This regulatory approval underscores CGP’s commitment to advancing medical device technology and enhancing patient care in the critical area of stroke treatment.- Flcube.com
